Merck Study: mRNA Technology a ‘Game Changer’ for Asia-Pacific Vaccine Manufacturers
- Written by The Bulletin

- 87% of respondents deemed mRNA a key modality for the future
- More than 60% vaccine makers surveyed plan revamp or new facilities for mRNA manufacturing to meet demand
- Skilled personnel, tech-transfer expertise, reliable supply chain, and regulatory guidelines critical to new technology adoption
SINGAPORE - Media OutReach - 31 May 2023 - According to a recent study sponsored by Merck, a leading science and technology company, mRNA technology is a "game-changer" for Asia-Pacific (APAC) vaccine manufacturers.
Read more: Merck Study: mRNA Technology a ‘Game Changer’ for Asia-Pacific Vaccine Manufacturers